GSK China Hepatitis B Push Raises Questions For Valuation And Dividend Risks

GSK (LSE:GSK) has entered an exclusive collaboration with Sino Biopharmaceutical, focused on bepirovirsen, a potential first in class hepatitis B treatment for the Chinese market. The partnership aims to accelerate the launch of bepirovirsen in China, targeting a large population affected by chronic hepatitis B. The agreement combines GSK’s R&D in hepatitis B with Sino Biopharmaceutical’s local healthcare presence to expand patient access. For GSK, which is focused on vaccines and specialty medicines, this move adds weight to its infectious disease pipeline in one of the world’s largest healthcare markets. China has a substantial hepatitis B burden, so any progress on a new treatment option is likely to attract attention from both healthcare providers and investors following LSE:GSK. For you as an investor, the collaboration highlights how GSK is working with local partners to pursue opportunities in large disease areas with significant unmet medical need. The pace of development, regulatory progress and eventual uptake of bepirovirsen in China will be key factors to monitor over time when assessing the impact of this agreement on GSK’s broader hepatitis B ambitions. Stay updated on the most important news stories for GSK by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on GSK. LSE:GSK Earnings & Revenue Growth as at May 2026 We've flagged 3 risks for GSK. See which could impact your investment. Quick Assessment ✅ Price vs Analyst Target: At £18.45, GSK trades about 9% below the £20.30 analyst price target. ✅ Simply Wall St Valuation: GSK is flagged as trading 59.1% below estimated fair value, which is a large discount. ❌ Recent Momentum: The share price is down 15.2% over the last 30 days. To decide whether to buy, sell or hold GSK, investors can review the latest analysis in Simply Wall St's company report on GSK's fair value. Key Considerations 📊 The Sino Biopharmaceutical tie up extends GSK’s hepatitis B ambitions into China, which has a large patient pool for a potential first in class treatment. 📊 It may be useful to watch how Chinese regulators treat bepirovirsen, any disclosed milestones in the collaboration, and whether analyst targets move from the current £20.30 consensus. ⚠️ Existing flags around dividend stability and debt levels mean investors may want to see how any China related spending or deal terms affect cash flows. Dig Deeper For a broader view of potential risks and opportunities, take a look at the complete GSK analysis. You can also visit the community page for GSK to see how other investors think this news may influence the company's narrative. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for Free